<DOC>
	<DOCNO>NCT02392624</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study evaluate efficacy safety subcutaneous omalizumab add-on therapy 48 week . After complete initial 24-week open-label treatment period omalizumab 300 mg every 4 week , participant respond omalizumab randomize 3:2 ratio ( omalizumab : placebo ) either continue omalizumab transition placebo 24 week .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety Omalizumab Through 48 Weeks Participants With Chronic Idiopathic Urticaria ( CIU )</brief_title>
	<detailed_description />
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Adolescents adult age group 1275 year Diagnosis CIU refractory H1 antihistamines baseline Presence itch hive least 8 consecutive week enrollment despite current use H1 antihistamine treatment ( four time approve dose ) time period Receiving H1 antihistamine treatment ( four time approve dose ) CIU least 3 consecutive day immediately prior screen visit continue current use day initial screen CIU diagnosis great equal 6 month Willing able complete daily symptom eDiary duration study Treatment investigational agent within 30 day initial screen visit Body weight less ( &lt; ) 20 kilogram ( kg ) Clearly define underlying etiology chronic urticarias CIU Evidence parastic infection Atopic dermatitis skin disease associate pruritus Previous treatment omalizumab within 1 year prior screen Participants may take treatment period take within 30 day screen follow medications/treatments : regular ( daily/every day ) hydroxychloroquine , methotrexate , mycophenolate , cyclosporine , cyclophosphamide , Intravenous Immunoglobulin G ( IVIG ) plasmapheresis Regular ( daily/every day ) doxepin ( oral ) use within 14 day prior screen</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>